Almost half of patients with metastatic renal-cell carcinoma (mRCC) are classified as intermediate risk by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. The aim of this study was to evaluate whether baseline C-reactive protein (CRP) levels predict overall survival (OS) in intermediate-risk group mRCC patients.
Data from 107 intermediate-risk group mRCC patients receiving first-line targeted therapy were retrospectively reviewed. We evaluated the correlation between baseline CRP levels as well as other indices and OS.
Of the 107 patients with intermediate-risk disease, 46 patients (43%) were classified as having elevated CRP levels. The elevation of pretreatment serum CRP levels was the independent prognostic factor of OS in patients with intermediate risk (hazard ratio, 4.609; P = .001). The 1- and 3-year survival rates of patients with intermediate-nonelevated CRP were 90.0% and 64.7% compared to the favorable-risk group, at 92.1% and 68.5%, respectively. In contrast, the 1- and 3-year survival rates of patients with intermediate-elevated CRP were 80.5% and 37.4% compared to the poor-risk group, at 65.2% and 24.2%, respectively.
Baseline CRP levels could divide mRCC patients in the intermediate-risk group into 2 prognostic subgroups.
Clinical genitourinary cancer. 2018 Mar 27 [Epub ahead of print]
Kimiharu Takamatsu, Ryuichi Mizuno, Minami Omura, Shinya Morita, Kazuhiro Matsumoto, Kazunobu Shinoda, Takeo Kosaka, Toshikazu Takeda, Toshiaki Shinojima, Eiji Kikuchi, Hiroshi Asanuma, Masafumi Oyama, Shuji Mikami, Mototsugu Oya
Department of Urology, Keio University School of Medicine, Tokyo, Japan., Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: ., Department of Uro-oncology, Saitama Medical University International Medical Center, Hidaka, Japan., Division of Diagnostic Pathology, Keio University Hospital, Tokyo, Japan.